Tumor-derived galectin-1 (Gal-1), a ß-galactoside-binding S-type lectin, has been shown to encourage T cell death and promote T cell-mediated tumor immune escape. In this report, we show that patients with leukemic cutaneous T cell lymphomas (L-CTCL), known to have limited complexity of their T cell repertoires, have a predominant T helper type-2 (Th2) cytokine profile and significantly elevated plasma levels of Gal-1 compared with healthy controls. Circulating clonal malignant T cells were a major source of Gal-1. The conditioned supernatant of cultured malignant T cells induced a β-galactoside-dependent inhibition of normal T cell proliferation and a Th2 skewing of cytokine production. These data implicate Gal-1 in development of the Th2 phenotype in patients with advancedstage CTCL and highlight the Gal-1 -Gal-1 ligand axis as a potential therapeutic target for enhancing anti-tumor immune responses.
Introduction
Contraction of the T cell repertoire and Th2 cytokine skewing are two immunosuppressive features linked to high morbidity and mortality of patients with leukemic cutaneous T cell lymphoma (L-CTCL) [1] [2] [3] [4] [5] . Certain soluble factor(s) expressed by clonal malignant cells or dermal fibroblasts (e.g. IL-18, eotaxins) could be responsible for this immunologic signature; nevertheless, mechanistic evidence on how these cells elicit their immunoregulatory function is still incomplete 6, 7 . Recently, the β-galactoside binding protein, galectin-1 (Gal-1), has been implicated in the induction of a Th2 signature and suppression of anti-tumor immune responses in patient's with Hodgkin's lymphoma 8, 9 . Gal-1 functions as a homodimer with affinity for N-acetyllactosamine-bearing glycoproteins on effector T cells that, upon engagement, induces pro-apoptotic and/or immunosuppressive activities 10, 11 . Gal-1-binding interactions induce deletion of pro-inflammatory T helper (Th)-1 and Th17 cells, but spare naïve, regulatory and Th2 cells, leading to a tolerogenic environment that favors tumor immune escape 12, 13 . In fact, in patients with Hodgkin's disease, increased Gal-1 expression is correlated with poor prognoses and implicated as a biomarker of disease progression 14 .
Though a prior study shows that Gal-1 expression is elevated in epidermotropic malignant T cells in patients with mycosis fungoides 15 , its presence and role in more advanced leukemic forms of CTCL have not been addressed. Here, we show that clonal malignant T cells in patients with Stages III-IV CTCL exhibited a Th2 cytokine signature and high intracellular Gal-1 expression. Moreover, L-CTCL patients exhibited higher plasma Gal-1 levels than healthy controls, and conditioned supernatants from primary L-CTCL cell cultures significantly attenuated normal T cell proliferation and diminished Th1 responses in a β-galactoside-dependent manner. Collectively, these data suggest that elevated levels of Gal-1 in L-CTCL patients may inhibit the proliferation of non-malignant T cells and favor Th2 skewing, leading to impaired antitumor responses and increased susceptibility to infection.
These studies suggest that neutralization of Gal-1-Gal-1 ligand interactions may be an effective strategy for enhancing anti-tumor immune responses in L-CTCL patients. (Table S1B ) and were performed in triplicate. For proliferation assays, CFSE-labeled T cells were cultured in L-CTCL-conditioned medium + IL-2 (25U/ml) (Peprotech) (+/-50mM lactose) or with 0.25µM Gal-1hFc for an additional 72h followed by FACS analysis.
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Results and Discussion
Prior reports show that L-CTCL patients have contracted T cell repertoires, a marked Th1/Th2 cytokine imbalance and are highly susceptible to opportunistic infections 3 . Recently, these findings have been associated with increased Gal-1 levels in patients with Hodgkin's lymphoma 8 . To study Gal-1's role in the pathogenesis of these immunosuppressive features, we studied circulating T cells in L-CTCL patients with elevated CD4/CD8 ratios and clonal malignant T cells that could be identified by staining with anti-TCR-Vβ mAbs ( Figure 1A, B) . Clonal T cells in L-CTCL patients expressed a distinctive Th2 signature characterized by elevated expression of IL-4 and IL-13 ( Figures 1C-D and   S1A ). Notably, we also found increased levels of IL-10 in clonal malignant CD4 + cells and in CD8 + T
cells of L-CTCL patients compared with healthy controls (Figures 1C-E).
To determine if Gal-1 could be contributing to the immunologic abnormalities observed in patients with L-CTCL, we quantified plasma Gal-1 levels in L-CTCL patients and compared them to healthy controls. As reported for other solid and hematologic malignancies 18, 19 , Gal-1 plasma levels were significantly elevated in patients with active L-CTCL and diminished during remission ( Figure 1F and Table S1A ). Moreover, analyses of intracellular Gal-1 and Gal-1 immunoblots of CTCL HUT78 cell lysates ( Figure S1B ) indicated that the malignant T clones were the main Gal-1 source in the PBMC compartment of L-CTCL patients ( Figure 1G) . Additionally, we found that Gal-1 was expressed in circulating T cells at three distinct levels (lo, (Figures 2G and S2B ).
In conclusion, our work suggests that L-CTCL-derived Gal-1 may impair the viability, proliferation and Th1 responses of non-malignant T cells, leading to a systemic Th2 bias that favors tumor survival and likely contributes to the observed susceptibility of these patients to infections. These Statistically significant difference compared with lactose-treated control using Student's paired t-test, *P≤0.05, **P≤0.001.
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